Dr. Crawford on PSA Testing for Prostate Cancer

E. David Crawford, MD
Published: Tuesday, Mar 07, 2017



E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.

In the future of prostate cancer, it is important to find men who will respond to treatment and not just overtreat them, explains Crawford. Appropriate PSA testing and analysis can help reduce overtreatment.

Crawford simplifies PSA testing by stating that a PSA less than 1.5 is a cutoff point where the patient can return for testing in 5 years, if the PSA is greater than 1.5 then further testing is required.
 


E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.

In the future of prostate cancer, it is important to find men who will respond to treatment and not just overtreat them, explains Crawford. Appropriate PSA testing and analysis can help reduce overtreatment.

Crawford simplifies PSA testing by stating that a PSA less than 1.5 is a cutoff point where the patient can return for testing in 5 years, if the PSA is greater than 1.5 then further testing is required.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x